Trial
NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
National Comprehensive Cancer Network; GlaxoSmithKline
Condition
CLL
Intervention
Ofatumumab
Why stopped
Terminated early due to change in practice.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-29